A5044050290- Neuroscience and Neuropharmacology Research
- Memory and Neural Mechanisms
- Functional Brain Connectivity Studies
- Neurotransmitter Receptor Influence on Behavior
- Schizophrenia research and treatment
- Neuroendocrine regulation and behavior
- Mental Health Research Topics
- Tryptophan and brain disorders
- Circadian rhythm and melatonin
- Receptor Mechanisms and Signaling
- Stress Responses and Cortisol
- Neuroinflammation and Neurodegeneration Mechanisms
- Sleep and Wakefulness Research
- Olfactory and Sensory Function Studies
- Neural dynamics and brain function
- Treatment of Major Depression
- Nicotinic Acetylcholine Receptors Study
- Heart Rate Variability and Autonomic Control
- Cholinesterase and Neurodegenerative Diseases
- EEG and Brain-Computer Interfaces
- Alzheimer's disease research and treatments
- Congenital heart defects research
- Neurological disorders and treatments
- Amino Acid Enzymes and Metabolism
- Genetic Neurodegenerative Diseases
Boehringer Ingelheim (Germany)
2021-2025
Eli Lilly (United Kingdom)
2015-2024
Boehringer Ingelheim (Australia)
2024
Hospital Universitario de La Princesa
2023
Eli Lilly (United States)
2015-2022
University of St Andrews
2017
Merck & Co., Inc., Rahway, NJ, USA (United States)
2015
Merck (United Kingdom)
2010-2014
NHS Lanarkshire
2010-2013
MSD (UK) Limited (United Kingdom)
2010-2011
Background Attentional dysfunction is related to functional disability in patients with neuropsychiatric disorders such as schizophrenia, bipolar disorder, and Alzheimer's disease. Indeed, sustained attention/vigilance among the leading targets for new medications designed improve cognition schizophrenia. Although vigilance assessed frequently using continuous performance test (CPT) humans, few tests specifically assess rodents. Methods We describe 5-choice CPT (5C-CPT), an elaboration of...
// Chrysi Xintaropoulou 1 , Carol Ward Alan Wise 2 Hugh Marston 2, 4 Arran Turnbull 3 Simon P. Langdon Division of Pathology, Institute Genetics and Molecular Medicine, University Edinburgh, Western General Hospital, EH4 2XU, UK IOMET Pharma, Nine, Edinburgh BioQuarter, EH16 4UX, Breakthrough Breast Unit, Current Address: Eli Lilly Research Development, Windlesham, Surrey, GU20 6PH, Correspondence to: Langdon, e-mail: Simon.Langdon@ed.ac.uk Keywords: glycolysis, inhibitors, ovarian cancer,...
Abstract Expression of coherent and rhythmic circadian (≈ 24 h) variation behaviour, metabolism other physiological processes in mammals is governed by a dominant biological clock located the hypothalamic suprachiasmatic nuclei (SCN). Photic entrainment SCN mediated, part, vasoactive intestinal polypeptide (VIP) acting through VPAC 2 receptor. Here we used mice lacking receptor ( Vipr2 −/− ) to examine contribution this electrophysiological actions VIP on neurons, generation electrical...
The choice and appropriate use of animal models in drug discovery for Alzheimer's disease (AD) is pivotal to successful clinical translation novel therapeutics, yet true alignment research challenging. Current do not fully recapitulate the human disease, even exhibit various degrees regional pathological burden diverse functional alterations. Given this, relevant endpoints must be determined on a model-by-model basis. present work explores rTg4510 mouse model tauopathy as case study define...
The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) belong to a superfamily of structurally related hormones that includes glucagon, glucagon-like peptides, secretin, growth hormone-releasing hormone. Microinjection VIP or PACAP into the rodent suprachiasmatic nucleus (SCN) phase shifts circadian pacemaker antagonists, antisense oligodeoxynucleotides have been shown disrupt function. equal potency as agonists VPAC 2 receptor...
Background: Social dysfunction is an early manifestation of neuropsychiatric disorders that may relate to altered Default Mode Network (DMN) integrity. This study aimed replicate previous findings linking social with diminished resting-state DMN functional connectivity and task-based activation in response emotional faces across schizophrenia (SZ), Alzheimer's disease (AD), healthy controls (HC), extend these major depressive disorder (MDD). Methods: Resting-state fMRI data on implicit...
Background and Purpose Tacrolimus (FK506) is a potent immunosuppressant that presently in clinical use for prevention of allograft rejection. Recently, animal studies reporting significant reductions the volume tissue damage associated with cardiac, hepatic, cerebral ischemia suggest tacrolimus may also be management stroke. In present study, we examine whether neuroprotective effects tacrolimus, as assessed by histological outcome, are accompanied an amelioration skilled motor deficits...